

## Second-quarter biotech job picture

Michael Francisco

Johnson & Johnson has opened its first startup incubator outside the United States. Based in the MaRS Discovery District, JLABS @ Toronto will initially house 22 companies, with a capacity of 50. It also has a device and digital prototype laboratory, where resident startups can access IBM's Watson cognitive system.

In Europe, Novartis announced a \$1-billion investment in its biomanufacturing facilities in Austria to support the planned launch of five biosimilars by 2020. The drugs include biosimilars of autoimmune drug Enbrel (etanercept), neutropenia drug Neulasta (pegfilgrastim), autoimmune and cancer drug Rituxan (rituximab), autoimmune drug Humira (adalimumab) and autoimmune drug Remicade (infliximab).

Finally, Pfizer unveiled its plan to invest approximately \$350 million to develop a biotech center in Hangzhou, China, increasing its footprint

in the world's second-largest pharma market. The plant, Pfizer's first in China and third overall, will manufacture branded biologics and biosimilars for patients worldwide. China has recently taken steps to ease regulatory and market challenges faced by pharma companies. In February, China's Food and Drug Administration said it would prioritize the approval process for new drugs with clear clinical value.

Advertised biotech and pharmaceutical sector jobs in the job databases tracked by *Nature Biotechnology* during the second quarter of 2016 are shown in **Tables 1** and **2**. Other downsizings within the life sciences industry are shown in **Table 3**.

**Table 1 Who's hiring? Advertised openings at the 25 largest biotech companies**

Company <sup>a</sup>	Number of employees	Number of advertised openings <sup>b</sup>		
		Monster	LinkedIn	Naturejobs
Monsanto	22,400	599	403	1
Amgen	17,900	369	275	0
CSL	12,196	1,000+	40	0
WuXi PharmaTech	8,837	122	34	0
bioMerieux	8,379	18	20	0
PerkinElmer	7,700	149	63	0
Bio-Rad Laboratories	7,600	202	169	0
Biogen	7,550	338	192	0
Biocon	7,310	0	0	0
Gilead Sciences	7,000	291	274	0
IDEXX Laboratories	6,400	107	146	0
Novozymes	6,267	0	7	0
Celgene	6,012	449	67	257
Endo Pharmaceuticals	5,062	157	40	0
Shire	5,016	246	328	0
Qiagen	4,339	49	76	0
Illumina	3,700	222	227	0
Regeneron Pharmaceuticals	2,925	18	216	0
Actelion	2,493	14	7	0
Alexion Pharmaceuticals	2,273	138	101	0
Biotest Pharmaceuticals	2,158	0	1	0
Vertex Pharmaceuticals	1,830	150	212	0
BioMarin Pharmaceutical	1,681	0	67	0
CK Life Sciences	1,675	0	0	0
AMRI	1,668	144	81	0
Total		4,782+	3,046	258

<sup>a</sup>As defined in *Nature Biotechnology's* survey of public companies (33, 703–709, 2015).  
<sup>b</sup>As searched on Monster.com, LinkedIn.com and Naturejobs.com, 13 July 2016. Jobs may overlap.

**Table 2 Advertised job openings at the ten largest pharma companies**

Company <sup>a</sup>	Number of employees	Number of advertised openings <sup>b</sup>		
		Monster	LinkedIn	Naturejobs
Novartis	133,413	1,000+	54	2
Johnson & Johnson	126,500	1,000+	3,029	0
Sanofi	113,496	237	778	11
GlaxoSmithKline	98,702	132	13	2
Roche	88,509	1,000+	374	4
Pfizer	78,300	1,000+	85	0
Abbott Laboratories	77,000	808	278	1
Merck & Co.	70,000	1,000+	111	5
AstraZeneca	57,500	412	147	4
Teva Pharmaceutical	43,009	160	58	0
Total		6,749+	4,927	29

<sup>a</sup>Data obtained from Statista. <sup>b</sup>As searched on Monster.com, LinkedIn.com and Naturejobs.com, 13 July 2016. Jobs may overlap.

**Table 3 Selected biotech and pharma downsizings**

Company	Number of employees cut	Details
Bind Therapeutics	37	Cut 38% of workforce and filed for Chapter 11 bankruptcy in May and is in talks to be acquired by Pfizer.
Carbylan Therapeutics	17	Suspended development of Hydros-TA and is pursuing a strategic transaction, which may include a merger or acquisition of the company.
Clovis Oncology	108	Will reduce staff and contractor positions by 35% by year end compared to year end 2015 and will reprioritize resources from rociletinib to its next most-advanced candidate, ruca-parib.
Neuralstem	NA	Reducing headcount across all divisions to focus on developing NSI-189.
Mologen	17	Restructured to focus on lead product MGN1703 (lefitolimod); will halt development of MGN1601 until it has found a commercialization partner for lefitolimod.

NA, not available. Source: *BioCentury*.

Michael Francisco is a Senior Editor at *Nature Biotechnology*.